TrialBritish journal of clinical pharmacology2016

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

Oliver von Richter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.